P&T News: May 1995, Vol. 15, No. 11

Treatment of Lice and Scabies: Focus on Safety

Jacqueline Pilzer, Pharm.D., and Mary B. Ross, R.Ph., M.B.A.
Peer Review Status: Internally Peer Reviewed by Michael B. Edmond. M.D., M.P H., Assistant Professor, Division of General Medicine, Clinical Epidemiology and Health Services Research, Department of Internal Medicine


Various treatment choices are available for the eradication of lice and scabies. For many years lindane had been considered the treatment of choice; however, its use has recently come under scrutiny because of reports of neurotoxic side effects, particularly if used in excess of the manufacturers' recommendations. This review provides an overview of the treatment options for lice and scabies and outlines safety issues that need to be emphasized to patients when prescribing or recommending these medications (Table 1).

Lice
Head (Pediculus humanus capitis), pubic (Phthirus pubis), and body (Pedicures humanus corporis) lice are highly contagious and are one of the most common parasitic infestations causing dermatosis. Itching is the most common symptom of this infestation. The egg of the louse, also called the nit, can be seen deposited on the hair 3 to 4 mm from the scalp. While lice are usually associated with poor hygiene, overcrowding and unsanitary conditions, this is not always the case; lice actually affect all socioeconomic groups. Head lice are common in child care situations and in school-aged children. Transmission can occur by direct contact with infested individuals or indirectly by contact with their personal belongings such as combs, brushes, and hats. Pubic lice infestations are common in adolescents and young adults and are transmitted though sexual contact. Body lice are generally found on persons with poor hygiene. 1-3

Permethrin
Permethrin is currently the drug of choice for treating head lice in adults and children.4 However, the safety and efficacy have not been established in children less than two months of age.5 Permethrin has a low potential for toxicity; the most frequent adverse reaction is pruritus. This symptom may be a manifestation of the parasite itself, but may also be aggravated following treatment.5 Permethrin has a high cure rate and high ovicidal activity.2 One study showed that the cure rate following its application is higher than following the application of lindane; 99% of patients treated with permethrin were lice free 14 days after a single application versus 85% for the lindane-treated patients.6

Permethrin is available as a 1% cream rinse (Nix(R)) for the treatment of lice. The cream rinse should be applied after the hair has been washed with shampoo, rinsed with water and towel dried. An amount of cream rinse sufficient to saturate the hair and scalp is applied and allowed to remain on the hair for 10 minutes before rinsing off with water. A single treatment usually eliminates head lice infestation activity for up to 10 days. If live lice are observed seven days or more after the first application, a second treatment should be given.5 The nits may be removed with the nit comb provided in the package.

Pyrethrins with Piperonyl Butoxide
Pyrethrins with piperonyl butoxide (A-200,(R RID,(R)) R&(~# are natural pyrethrin compounds derived from certain flowers of the genus chrysanthemum. Due to possible cross allergenicity, it is suggested that people hypersensitive to ragweed avoid these products.7 Synthetic piperonyl butoxide is added to block detoxification of the pyrethrins by the parasite. These products are available as various nonprescription shampoos, gels or liquids. The selected product should be applied for 10 minutes after which the area needs to be rinsed well. ' Although the first treatment is often successful, ovicidal activity is low and repeat application is advised after 7 to 10 days to kill newly hatched lice.2 When applied appropriately, toxicity is low and it is usually limited to local irritation.

Lindane
Lindane (Kwell,-(R)gamma benzene hexachloride) has become a second-line treatment for head and pubic lice due to its potential toxicity, which is the highest of all pediculocides.2 3 Central nervous system (CNS) stimulation ranging from dizziness to convulsions has been reported, but these effects were almost always associated with accidental oral ingestion or overuse of the product.2 Animal studies indicate that the potential toxic effects are greater in the young.8 Lindane has also been shown to cause eczematous eruptions.8 Lindane should be used with caution in young children and during pregnancy and lactation.3 The use of lindane is contraindicated in patients with seizure disorders.8

Oil enhances the absorption of lindane; therefore, if the patient uses an oil-based hair dressing, it is recommended that the hair be shampooed and dried before applying lindane shampoo.8 It is very important not to exceed the recommended dosage and duration that the product is in contact with the skin. The health care professional must emphasize this important safety information to the patient.

A 1% lindane shampoo is available for the treatment of lice. Enough shampoo needs to be applied to dry hair to thoroughly wet the hair and the skin of the infested and adjacent areas. The shampoo should remain in place for only 4 minutes. After adding small amounts of water to form a good lather, the hair should be thoroughly rinsed and briskly towel dried. Nits may be removed with a fine toothed comb when the hair is dry. Ovicidal activity is low.2 Evidence of surviving lice seven days after treatment is an indication that an additional treatment is necessary. 8

Other Treatment Considerations
For infestation of eyelashes, petrolatum ophthalmic ointment should be applied 3 to 4 times per day for 8 to 10 days. Nits should be mechanically removed using tweezers.

For the eradication of body lice, pediculicides are not necessary. 1-3 Treatment consists of improved hygiene and washing .

To prevent reinfestation, clothing, bedding, and cloth toys can be disinfected by machine washing or drying using hot cycles, since temperatures exceeding 128.3°F for 5 minutes are lethal to lice and eggs.2 Dry cleaning or simply storing clothes in plastic bags for 10 days is also effective. For disinfecting combs and brushes, soaking in hot water for 10 minutes or washing with a pediculicide shampoo is recommended. With all types of hoe, it is important to examine and treat all contacts if necessary

Table 1. Drug Treatment Options for Lice and Scabies

Product

Prescription Status

Application Time

Adverse Effects/Warnings

LICE

Permethrin 1%* Cream Rinse (Nix[R])

OTC

10 minutes

Pruritis

Pyrethrins with Piperonyl Butoxide (RID,[R]A-200,[R]R&C,[R]others

OTC

10 minutes

Skin irritation

Lindane 1% Shampoo (Kwell[R], others)

Rx

4 minutes

Central nervous system toxicity, including seizures with overuse

Skin irritation

SCABIES

Permethrin 5%* Cream (Elimite[R])

Rx

8 to 14 hours

Mild tingling, burning

Lindane 1% Lotion or Cream (Kwell[R], others)

Rx

8 to 12 hours

Central nervous system toxicity including seizures with overuse

Skin irritation

Crotamiton 10% Cream or Lotion (Eurax[R])

Rx

24 hours, with a second application 24 hours later

Skin irritation

* Therapy of choice
NOTE: Permethrin 1% cream rinse, permethrin 5% cream, lindane 1% shampoo, lindane 1% lotion, and crotamiton 10% lotion are currently stocked at UIHC.

Scabies
Scabies is a contagious skin infestation caused by the arachnid mite Saroptes scabies The mite burrows beneath the stratum corneum and is characterized by intense itching and secondary inflammation. The most common infestation sites are the interdigital spaces of the fingers, the flexor surfaces of the wrists, the external male genitalia, the buttocks and the anterior axillary folds. The head and neck are usually not affected, except in infants The diagnosis can be made by identifying the mite under a microscope. The burrow may be visible to the naked eye and appears as a narrow slightly raised dark line, but often the burrows are obliterated by scratching long before a patient is seen by a physician. Scabies is often associated with poor hygiene and crowded conditions. T he mite Is endemic in many developing countries. Transmission usually occurs through bodily contact with an infested host, clothing, or bed linen. ~3

Permethrin
Permethrin 5 % cream (Elimite OR)) is the drug of choice for the treatment of scabies in infants, children, and pregnant or nursing women.2 It is not known whether permethrin is excreted in human milk and consideration should be given to temporarily discontinuing nursing, should the mother require therapy.9 The cream should be applied over the entire body below the head. Because scabies can affect the head, scalp, and neck in infants and young toddlers, treatment o f the entire body is required for this group.2 After being massaged into the skin, it must be removed by washing after 8 to 14 hours.

Usually 30 g is sufficient for the average adult. One application is usually curative. Side effects commonly include mild burning, tingling and erythema.9

Lindane
Lindane 1 % lotion and a ream (Kwell ' ) are second-line therapy for scabies because of toxicity concerns, particularly neurotoxicity.2 They should be used with caution in infants and pregnant women. The lotion should be applied to the dry skin in a thin layer and rubbed In thoroughly.10 Lindane should not he used following a bath or by persons with extensive dermatitis because of concerns of increased absorption and subsequent seizures.11 If crusted lesions are present, a tepid bath preceding the medication application is helpful in loosening them, but it is important to allow the skin to dry before using the lotion.1,10 Use on open cuts and extensive excoriations should be avoided as that may also lead to excess systemic absorption of lindane I Visually. 60 ml is sufficient for an adult. A total body application from the head down should be made and left on far 8 to 12 hours and then removed by thorough washing. One application is usually curative. Many patients will exhibit persistent pruritus after treatment, but this is rarely a sign of treatment failure. Retreatment is not indicated unless living mites can be demonstrated.1 Unnecessary skin contact should be avoided in those applying lindane therapy to others

Crotamiton
Crotamiton 10% cream or lotion (Eurax (R)) can also be used to treat scabies. However, this therapy is prone to treatment failure. anti usually requires a second application.1,2 A thin layer is applied uniformly to all skin surfaces and is left on the skin. A second application is advisable 24 hours later. The patient should take a cleansing bath 24 to 48 hours after the last application to rem()>e any ren ainlng drug. Retreatment may be necessary after 7 to 10 days if mites appear or new lesionsdevelop. Adverse effects may include allergic sensitivity and skin irritation.1

Other Treatment Considerations
To prevent reinfestation, bedding and clothing should be laundered in hot water and a hot drying cycle. The parasites do not survive more than 3 to 4 days without contact with the slain. Clothing that cannot be laundered should be removed from the patient and stored 101 a week or more to avoid reintestation.2 Fingernails should be trimmed because the space 11etw~#:en the fingernail and the skin mar harbor mites.3

Summary
Permethrin provides a highly effective ant safe treatment for the management of lice and scabies. Patients should be carefully counseled regarding: 1) the appropriate application of the respective products to ensure optimal effectiveness; 2) the potential toxicities that can occur with misuse and/or overapplication, particularly with lindane; and 3) the proper measures to take to prevent reinfestation Patients should also be counseled that pruritus may persist for several days post treatment and does not necessarily signets a treatment failure. Requests for refills or frequent purchase of nonprescription pediculocides should be a cute that additional patient education is needed.

References

1. AMA Drug Evaluations Annual 1994. Chicago: American Medical Association; 1994:1611-7.
2. 1994 Red Book: Report elf he Committee on Infectious Diseases 23rd ad. Elk Grove Village: American Academy of Pediatrics: 1994: 349-51, 417 9
3. Principles and Practice of Infectious Diseases. 4th ed. New Yank. Churchill Livingstone; 1995 2558-62.
4. Mod Lett Drugs Ther. 1993;35:111-22.
5. Burroughs Wellcome Co. Nix(R) Package Insert Research Triangle Park, NC 1993
6.AJDC. 1986;140:894-6.
7. SmithKJine Beecham. A200(R) Package Insert. Pittsburgh, PA 1993.
8. Pennex Pharmaceuticals. Lindane Shampoo USP 1% Package Insert. Morton Grove, IL 1993 June.
9.Herbert Laboratories. Elimite P'Crcam S8S Package Insert. Irvine CA 1990 Apnl.
10. Pennex Pharmaceuticals. Lilldane Lotion USP 1 A, Package Insert. Morton Gri ve, IL. 1993 June.
11. MMWR. 1993; 42(RR-14):95-7


Adverse Drug Reaction Report
Hemiparesis Associated with Sumatriptan Use

Shortly after sumatriptan (Imitrex(R) ) was approved by the FDA in 1993, reports of cerebrovascular events associated with its use began to appear in the literature. Two such cases are described below.

A 46-year-old man who had a 20-year history of migraine attacks began using sumatriptan. During the first two weeks of therapy, he injected himself with five subcutaneous doses of 6 mg each. A week following his last dose he developed a cerebral infarct and experienced symptoms of hypoasthesia, hemiparesis, and weakness in his right arm and leg. Computed tomography (CT) of the brain demonstrated an area of low attenuation in the left thalamic region. After three months of physiotherapy, the patient was completely recovered and his CT scan returned to normal.

The second case involved a 25-year-old woman who was first diagnosed with migraine during her first pregnancy at the age of 22. A year later, migraine headaches recurred when she began taking oral contraceptives. One month prior to admission, she had again resumed taking oral contraceptive. Migraine headaches again occurred heralded by teichopsia and left-orbital pain, followed by right-sided numbness and throbbing frontal headache. She was given one 6 mg dose of subcutaneous sumatriptan. Twelve hours after the dose, she developed a right hemiparesis (power 3 out of 5); however, her brain CT scan was normal. Her symptoms resolved within one week.

Both of these patients had no identified risk factor for vascular disease.

______
Abstracted from: Lancet. 1993;341:1091-2.
_______

When sumatriptan was first marketed, the manufacturer warned that individuals with underlying heart disease should not use the drug because of its potential to constrict coronary arteries. Post-marketing experience, including incidents similar to those described above, has prompted the manufacturer to revise labeling and include new warnings in the package insert. These additional warnings are:

__________
Source: "Dear Healthcare Professional" Letters. Sumatriptan (Imitrex L ). Cerenex Pharmaceuticals. Research Triangle Park, NC. August and November 1994.


Pharmacy and Therapeutics Subcommittee Actions

Drugs Added to Stock

COLCHICINE Injection: 500 mg/ml, 2 ml ampul Intravenous colchicine is used for the management of acute gouty arthritis attacks. Note: Injectable colchicine was discontinued by the manufacturer, but has recently been reintroduced.

FENTANYL Oral Lozenge: 200 mcg, 300 mcg, 400 mcg Fentanyl oral lozenges (Fentanyl Oralet(R)-Abbott) are indicated for anesthetic premedication in children and adults, and for use in anesthesia or monitored anesthesia care. Note: This product should be administered in monitored settings and by persons specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, including maintenance of a patient airway and assisted ventilation. Resuscitative treatments and equipment should be readily available.

HEPATITIS A INACTIVATED VACCINE Injection: 1440 EL.U. per 0.5 ml, pediatric strength Hepatitis A vaccine (Havrix(R)-SKB) is indicated for active immunization of persons 2 years of age against disease caused by hepatitis A virus. Note: The pediatric strength will be stocked as soon as it is commercially available.

IBUPROFEN Tablets: 100 mg Chewable Tablets: 50 mg These pediatric formulations of ibuprofen (Motrin(R)-McNeil) are indicated for the reduction of fever in patients aged 6 months or older and for the management of juvenile arthritis.

Drugs Deleted from Stock

CHLOROQUIN1E PHOSPHATE 250 mg TABLETS Discontinued by all manufacturers. The 500 mg strength is still available.

CLOFAZIMINE 100 mg (LAMPRENE(R) '9-Ciba) CAPSULES Discontinued by the manufacturer. The 50 mg strength is still available.

GLUCAGON 10 mg INJECTION Discontinued by the manufacturer. The 1 mg vial is still available.

POLYTEF PASTE Discontinued due to low use.

SODIUM CITRATE 0.3M SOLUTION This compounded product was deleted due to low use. Commercially available sodium citrate and citric acid solution (Bicitra (R)) is the stocked alternative product.

THEOPHYLLINE 250 mg EXTENDED-RELEASE (SLO PHYLLIN(R) GYROCAPS) CAPSULES Discontinued by the manufacturer. The 125 mg strength is still available.

Product Changes

CROMOLYN Cromolyn 4 % Ophthalmic Solution is again commercially available (Crolom(R)-Bausch & Lamb).

TERAZOSIN All strengths of terazosin (Hytrin(R)) have been reformulated to capsules.

Next Page | Title Page